Novavido Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $1.7M

  • Investors
  • 5

Novavido General Information

Description

Developer of medical devices designed to offer treatment to blind patients affected by retinitis pigmentosa. The company's devices utilize nanotechnology-based medical technology to restore vision in patients with retinitis pigmentosa, a condition that can replace photoreceptors damaged by retinal degeneration, enabling patients to regain their vision across the entire field of view.

Contact Information

Website
www.novavido.it
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Via Paolo Nanni Costa 20
  • 40133 Bologna(Emilia-Romagna)
  • Italy
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Other Devices and Supplies
Vertical(s)
Nanotechnology, HealthTech, Life Sciences
Corporate Office
  • Via Paolo Nanni Costa 20
  • 40133 Bologna(Emilia-Romagna)
  • Italy

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novavido Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Seed Round 23-Jun-2021 $1.7M Completed Product In Beta Test
1. Accelerator/Incubator 01-Jan-2021 Completed Product In Beta Test
To view Novavido’s complete valuation and funding history, request access »

Novavido Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 2

    Pending

  • Expiring in next 12 mo

Novavido Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026013635-A1 Injectable nanoparticle suspension for vision recovery Pending 12-Jul-2024
EP-4669310-A1 Oxidized poly(3-hexylthiophene) nanoparticles for treating degenerative retinal diseases Pending 21-Feb-2023
WO-2024176066-A1 Oxidized poly(3-hexylthiophene) nanoparticles for treating degenerative retinal diseases Inactive 21-Feb-2023 A61K9/0048

Novavido Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novavido Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alfasigma (Pharmaceuticals) Corporation Minority
Club2021 Venture Capital Minority
Istituto David Chiossone Venture Capital Minority
Utopia SIS Venture Capital Minority
G-Factor Accelerator/Incubator
To view Novavido’s complete investors history, request access »

Ready to get started?

Request a free trial

Novavido FAQs

  • When was Novavido founded?

    Novavido was founded in 2021.

  • Where is Novavido headquartered?

    Novavido is headquartered in Bologna, Italy.

  • What is the size of Novavido?

    Novavido has 2 total employees.

  • What industry is Novavido in?

    Novavido’s primary industry is Therapeutic Devices.

  • Is Novavido a private or public company?

    Novavido is a Private company.

  • What is Novavido’s current revenue?

    The current revenue for Novavido is .

  • How much funding has Novavido raised over time?

    Novavido has raised $1.7M.

  • Who are Novavido’s investors?

    Alfasigma (Pharmaceuticals), Club2021, Istituto David Chiossone, Utopia SIS, and G-Factor have invested in Novavido.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process